BG104915A - Azabicyclic 5hti receptor ligands - Google Patents

Azabicyclic 5hti receptor ligands

Info

Publication number
BG104915A
BG104915A BG104915A BG10491500A BG104915A BG 104915 A BG104915 A BG 104915A BG 104915 A BG104915 A BG 104915A BG 10491500 A BG10491500 A BG 10491500A BG 104915 A BG104915 A BG 104915A
Authority
BG
Bulgaria
Prior art keywords
azabicyclic
receptor ligands
5hti
5hti receptor
compounds
Prior art date
Application number
BG104915A
Other languages
Bulgarian (bg)
English (en)
Inventor
Gene BRIGHT
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG104915A publication Critical patent/BG104915A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Luminescent Compositions (AREA)
BG104915A 1998-04-09 2000-11-07 Azabicyclic 5hti receptor ligands BG104915A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8123798P 1998-04-09 1998-04-09
PCT/IB1999/000457 WO1999052907A1 (en) 1998-04-09 1999-03-18 Azabicyclic 5ht1 receptor ligands

Publications (1)

Publication Number Publication Date
BG104915A true BG104915A (en) 2001-07-31

Family

ID=22162936

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104915A BG104915A (en) 1998-04-09 2000-11-07 Azabicyclic 5hti receptor ligands

Country Status (40)

Country Link
US (2) US6525048B1 (cs)
EP (1) EP1070065B1 (cs)
JP (1) JP3496759B2 (cs)
KR (1) KR100378931B1 (cs)
CN (1) CN1117092C (cs)
AP (1) AP1175A (cs)
AR (1) AR015751A1 (cs)
AT (1) ATE248838T1 (cs)
AU (1) AU749254B2 (cs)
BG (1) BG104915A (cs)
BR (1) BR9909522A (cs)
CA (1) CA2327782A1 (cs)
CO (1) CO5080727A1 (cs)
CZ (1) CZ20003684A3 (cs)
DE (1) DE69910997T2 (cs)
DK (1) DK1070065T3 (cs)
DZ (1) DZ2756A1 (cs)
EA (1) EA003400B1 (cs)
ES (1) ES2204154T3 (cs)
HR (1) HRP20000653A2 (cs)
HU (1) HUP0102400A3 (cs)
ID (1) ID26086A (cs)
IL (1) IL138629A0 (cs)
IS (1) IS5641A (cs)
MA (1) MA26619A1 (cs)
MY (1) MY133390A (cs)
NO (1) NO20005004L (cs)
NZ (1) NZ507010A (cs)
OA (1) OA11496A (cs)
PA (1) PA8469101A1 (cs)
PE (1) PE20000413A1 (cs)
PL (1) PL343408A1 (cs)
PT (1) PT1070065E (cs)
SK (1) SK14782000A3 (cs)
TN (1) TNSN99056A1 (cs)
TR (1) TR200002932T2 (cs)
TW (1) TW555758B (cs)
WO (1) WO1999052907A1 (cs)
YU (1) YU59400A (cs)
ZA (1) ZA992596B (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
UA62015C2 (en) 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
US7718705B1 (en) 1999-09-03 2010-05-18 Eli Lilly And Company Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
GB2362826A (en) * 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
ATE409475T1 (de) * 2001-02-20 2008-10-15 Dinan Timothy Gerard Behandlung von fibromyalgie mit pindolol
CN100389115C (zh) * 2003-03-12 2008-05-21 辉瑞产品公司 吡啶氧基甲基和苯并异唑氮杂二环衍生物
JP2007519705A (ja) * 2004-01-29 2007-07-19 ファイザー・プロダクツ・インク Ｃｎｓ障害を治療するための非定型抗精神病薬とアミノメチルピリジルオキシメチル／ベンゾイソオキサゾールアザビシクロ誘導体の組合せ
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
AR049478A1 (es) 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
AR048112A1 (es) * 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
CA2571555A1 (en) * 2004-06-22 2006-01-05 Pfizer Products Inc. Diazabicyclic histamine-3 receptor antagonists
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
JP2008512441A (ja) * 2004-09-10 2008-04-24 ファイザー・プロダクツ・インク ピリジルオキシメチル、及びベンズイソオキサゾール・アザビシクロ誘導体を使用する、認知障害の治療方法
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF A SPECIFIC SEROTONIN REUPSORPTION INHIBITOR AND A SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106849A (en) * 1988-05-24 1992-04-21 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
MX19222A (es) * 1989-01-23 1993-12-01 Pfizer Agentes ansioliticos bis-aza-biciclicos
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
ATE146178T1 (de) * 1991-09-25 1996-12-15 Pfizer Neuroleptisch 2-substituierte perhydro-1h- pyrido(1,2-a>pyrazine
US5262428A (en) * 1992-03-13 1993-11-16 Wake Forest University Biologically active tropane derivatives
EP0646116B1 (en) * 1992-06-16 1999-10-13 Pfizer Inc. Process and intermediates for bis-aza-bicyclic anxiolytic agents
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
US5731307A (en) * 1994-09-30 1998-03-24 Pfizer, Inc. Neuroleptic 2,7-disubtituted perhydro-1h-pyrido 1, 2-A!pyrazines
US5614523A (en) * 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems

Also Published As

Publication number Publication date
MY133390A (en) 2007-11-30
US6887905B2 (en) 2005-05-03
PE20000413A1 (es) 2000-05-25
IL138629A0 (en) 2001-10-31
NO20005004L (no) 2000-11-27
OA11496A (en) 2004-05-14
AU749254B2 (en) 2002-06-20
WO1999052907A1 (en) 1999-10-21
HK1035719A1 (en) 2001-12-07
HUP0102400A3 (en) 2002-10-28
JP3496759B2 (ja) 2004-02-16
EP1070065B1 (en) 2003-09-03
MA26619A1 (fr) 2004-12-20
PL343408A1 (en) 2001-08-13
YU59400A (sh) 2003-10-31
DK1070065T3 (da) 2003-11-24
CN1117092C (zh) 2003-08-06
KR100378931B1 (ko) 2003-04-07
NO20005004D0 (no) 2000-10-04
CO5080727A1 (es) 2001-09-25
PT1070065E (pt) 2003-12-31
DE69910997T2 (de) 2004-05-19
AP9901502A0 (en) 1999-06-30
SK14782000A3 (sk) 2002-06-04
TW555758B (en) 2003-10-01
AU3268799A (en) 1999-11-01
BR9909522A (pt) 2000-12-19
AP1175A (en) 2003-06-04
TR200002932T2 (tr) 2001-01-22
EA200000910A1 (ru) 2001-04-23
AR015751A1 (es) 2001-05-16
DE69910997D1 (de) 2003-10-09
PA8469101A1 (es) 2000-09-29
HRP20000653A2 (en) 2001-04-30
CZ20003684A3 (cs) 2002-03-13
ID26086A (id) 2000-11-23
JP2002511469A (ja) 2002-04-16
CA2327782A1 (en) 1999-10-21
CN1305477A (zh) 2001-07-25
EP1070065A1 (en) 2001-01-24
IS5641A (is) 2000-09-26
ATE248838T1 (de) 2003-09-15
NZ507010A (en) 2003-05-30
HUP0102400A2 (hu) 2001-11-28
KR20010042527A (ko) 2001-05-25
EA003400B1 (ru) 2003-04-24
ES2204154T3 (es) 2004-04-16
DZ2756A1 (fr) 2003-09-15
US20030181458A1 (en) 2003-09-25
US6525048B1 (en) 2003-02-25
ZA992596B (en) 2000-10-08
TNSN99056A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
BG104915A (en) Azabicyclic 5hti receptor ligands
BG102704A (en) Fungicide 2-methoxybenzophenons
BG103485A (en) Ketobanzamides as calpain inhibitors
GB9722520D0 (en) Compounds
CA2341291A1 (en) Pyridine ketones useful as herbicides
TR200103273T2 (tr) Hemisentetik yöntem ve yeni bileşimler.
BG105784A (en) Triazole compounds with dopamine-d3-receptor affinity
BG105028A (en) Bridged indenopyrrolocarbazoles
BG106340A (en) Substituted oxoazaheterocyclyl compounds
BG105711A (en) 3-azabicyclo[3.1.0]hexane derivatives as opiate receptors ligands
MY132671A (en) Substituted 6,6-hetero-bicyclic derivatives
JO2654B1 (en) Multiple aryl caroxa amides are useful as lipid - lowering agents
AP2001002103A0 (en) Substituted phenyl derivatives, their preparation and use.
WO2001017973A3 (de) Neue herbizide
SI0971922T1 (en) Tetrahydropyrido compounds
BG105710A (en) 5ht1 antagonists for antidepressant therapy
BG105847A (en) Calcilytic compounds
MXPA02009549A (es) Imidazopiridinas triciclicas.
BG104232A (bg) Заместени 1,2,3,4,5,6-хексахидро-2,6-метано-3-бензазоцин- 10-оли, метод за тяхното получаване и приложението им като лекарствени средства
IN187760B (cs)
BG106002A (en) Process for preparing pesticidal intermediates
CA2281702A1 (en) (4-piperidinyl)-1h-2-benzopyran derivatives useful as antipsychotic agents
GR3034406T3 (en) Intermediates for the preparation of 2-imidazoline-5-ones
GB9806409D0 (en) Processes for preparing intermediates
ZA983231B (en) Substituted benzyloxyimino compounds.